New combo aims to stall aggressive lung cancer

NCT ID NCT07376499

Not yet recruiting Disease control Sponsor: China Medical University, China Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests a four-drug maintenance therapy for people with extensive small cell lung cancer that has responded to initial treatment. The combination includes liposome irinotecan, platinum chemotherapy, an immune checkpoint inhibitor (toripalimab), and an anti-angiogenic drug (anlotinib). The goal is to see if this regimen can delay cancer progression and improve survival. The study plans to enroll 31 participants and is not yet recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Liposome irinotecan, platinum (carboplatin or cisplatin), anlotinib, and toripalimab
What this could lead to: If successful, this combination could offer a new maintenance option to keep extensive small cell lung cancer from progressing longer after initial treatment.
What could go wrong: This is a small, early-phase (phase 2) trial with only 31 people, so results may not apply broadly. The drug combo also carries risks like severe side effects from chemotherapy and immune-related reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SMALL CELL LUNG CANCER

More trials for these conditions

Other studies related to the condition(s) this trial covers.